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Abstract: Melanoma often recurs in patients after the removal of the primary tumor, suggesting the
presence of recurrent tumor-initiating cells that are undetectable using standard diagnostic methods.
As cell fusion has been implicated to facilitate the alteration of a cell’s phenotype, we hypothesized
that cells in the peritumoral stroma having a stromal phenotype that initiate recurrent tumors
might originate from the fusion of tumor and stromal cells. Here, we show that in patients with
BRAFV600E melanoma, melanoma antigen recognized by T-cells (MART1)-negative peritumoral
stromal cells express BRAFV600E protein. To confirm the presence of the oncogene at the genetic level,
peritumoral stromal cells were microdissected and screened for the presence of BRAFV600E with a
mutation-specific polymerase chain reaction. Interestingly, cells carrying the BRAFV600E mutation
were not only found among cells surrounding the primary tumor but were also present in the stroma
of melanoma metastases as well as in a histologically tumor-free re-excision sample from a patient
who subsequently developed a local recurrence. We did not detect any BRAFV600E mutation or protein
in the peritumoral stroma of BRAFWT melanoma. Therefore, our results suggest that peritumoral
stromal cells contain melanoma-derived oncogenic information, potentially as a result of cell fusion.
These hybrid cells display the phenotype of stromal cells and are therefore undetectable using routine
histological assessments. Our results highlight the importance of genetic analyses and the application
of mutation-specific antibodies in the identification of potentially recurrent-tumor-initiating cells,
which may help better predict patient survival and disease outcome.
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1. Introduction
Melanoma is a highly aggressive malignancy, which often gives rise to metastases and local
recurrences following tumor-free staging [1,2]. The histopathological examination of excisional
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and re-excisional samples and sentinel lymph node biopsies constitutes a fundamental part of the
prognostic evaluation of this disease. Thus, the ability to detect recurrent-tumor-initiating cells in the
tissue sample is highly important both for prognostic purposes and for managing the disease.
As a result of tumor heterogeneity, tumor cells often differentially express phenotypic markers [3,4],
rendering their detection during routine histological assessments difficult. Epithelial-mesenchymal
transition, dedifferentiation, and acquisition of stem-cell characteristics have been shown to make
tumor cells more malignant [3,5,6]. Although the mechanisms by which these features are acquired
have not yet been fully elucidated, epigenomic and genomic alterations are thought to be the key
drivers of this malignant heterogeneity [7,8].
Cell fusion has been implicated in playing a major role in tumor progression in numerous tumor
types [9–11]. Several studies have found that hybrid cells of tumor-stromal cell fusion are more
malignant than the parental tumor cells and contribute to tumor heterogeneity [12]. Moreover, it has
been shown that cell fusion might alter the phenotype of the parental cells [13–15] and that it can be an
alternative way of epithelial mesenchymal transition [16–18].
Therefore, we hypothesized that tumor cells could similarly adopt a stromal phenotype by fusing
with peritumoral stromal cells, while maintaining their oncogenic properties. Such fusion may lead to
a cell type with mixed features that can evade immune recognition and clinical detection and therefore
promote tumor recurrence. Thus, the detection of such hybrid cells in the intra- and peritumoral
stroma could be significant for the accurate histopathological diagnosis and subsequent therapy.
2. Results
2.1. The BRAFV600E Protein Is Expressed in Subpopulations of Peritumoral Stromal Cells
To identify potential recurrent tumor-initiating cells, we screened for peritumoral cells that display
a stromal phenotype but carry tumor-derived oncogenic information. For this we performed dual
immunohistochemical staining on n = 11 patient-derived tissue samples of BRAFV600E melanoma
with MART1 (melanoma antigen recognized by T-cells) and BRAFV600E. BRAFV600E is an oncogenic
somatic mutation present in approximately 50%–60% of malignant melanomas. The staining
revealed that, in addition to melanoma cells, BRAFV600E is also expressed in some subpopulations
of MART1´ peritumoral stromal cells with fibroblast and macrophage morphology (Figure 1a,b).
To investigate whether the mutant protein originated from the tumor cells, we tested the stroma of
n = 5 BRAFWT melanomas for the presence of the BRAFV600E protein. However, we could not detect the
mutant protein in BRAFWT melanoma tissue samples (Supplementary Materials Figure S1), suggesting
that the presence of the mutation in the stromal cells could not occur without the neighboring
melanoma cells carrying the mutation. Nevertheless, though the antibody has been reported to
be highly specific, and we did not see any specific signals in BRAFWT melanoma tissue samples,
we cannot rule out nonspecific staining especially in case of macrophages.
2.2. Some Peritumoral Fibroblasts and Macrophages Carry the BRAFV600E Mutation in Primary Melanoma,
Melanoma Metastasis and a Tumor-Free Re-Excision Sample
We wanted to confirm that the staining we observed in the BRAFV600E samples was specific,
so we examined whether this oncogenic information is also present in the peritumoral cells at the
genetic level. Therefore, we dual-stained BRAFV600E primary melanoma tissue samples with MART1
and either the fibroblast marker smooth muscle actin (SMA) or the monocyte-macrophage marker
CD68, and isolated cell compartments consisting of 20–50, clearly MART1´ but either SMA+ or CD68+
cells with fibroblast and macrophage morphology, respectively, using laser-capture microdissection
(Figure 2a,b). Subsequent allele specific mutation detection PCR analyses performed on the dissected
stromal cells revealed that the BRAFV600E mutant allele was present in peritumoral MART1´/SMA+
fibroblasts and MART1´/CD68+ macrophages. In addition to primary melanoma tissue samples,
such peritumoral stromal cells carrying the melanoma-derived mutation were detected in lymph node
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and cutaneous melanoma metastases (Figure 2c). Surprisingly, BRAFV600E was also detected when
analyzing MART1´macrophages dissected from a histologically tumor-free re-excision sample from a
patient who subsequently developed a local recurrence. Having dissected peritumoral stromal cells
from BRAFWT melanoma tissue samples, we only detected the wild-type allele, providing further
evidence that BRAFV600E is only present in peritumoral cells that are adjacent to a mutant tumor.
In total, we examined 86 dissected samples of 19 patients, and out of 12 patients with BRAFV600E
melanoma, we found BRAFV600E-containing peritumoral cells in the tissue samples of five patients.
The proportion of mutant alleles detected in these cell populations varied between 0.5% and 30%
(Table 1 and Supplementary Materials Table S1).
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Figure 1. Peritumoral stromal cells express the melanoma-derived oncogenic BRAFV600E protein.  
(a,b) Tissue samples of a patient with BRAFV600E melanoma stained for the melanoma marker 
melanoma antigen recognized by T-cells (MART1) (red), the BRAFV600E mutant protein (brown)  
and hematoxylin (blue). Brown arrows indicate peritumoral MART1−/BRAFV600E+ cells displaying 
fibroblast (a) or macrophage (b) morphology. Blue arrows indicate MART1−/BRAFV600E− stromal cells 
(light blue from hematoxylin). Red lines indicate MART1+ melanoma cells. Black bars indicate 50 µm. 
Table 1. Peritumoral fibroblasts and macrophages in BRAFV600E melanoma carry the melanoma-derived 
BRAFV600E mutation at the genetic level. 
Tissue 1 
Npos/Nex 2,3
Fibroblasts 4 Dissected Macrophages 5 Dissected
BRAFV600E primary melanoma 2/2 1/1 
BRAFV600E melanoma metastasis 2/4 2/4 
Histologically tumor-free tissue (from 
patients with BRAFV600E melanoma) 0/4 1/3 
BRAFWT primary melanoma 0/4 0/1 
1 Tissue samples were dual-stained either with melanoma antigen recognized by T-cells (MART1) & 
smooth muscle actin (SMA) or with MART1 & CD68 and examined by a certified pathologist (IBN);  
2 Npos: number of patients where BRAFV600E-positive peritumoral stromal cells were found; Nex: the 
number of patients examined; 3 Dissected cell samples were considered positive for BRAFV600E if the 
prevalence of the mutant allele was higher than 0.39% (ΔCt < 8); 4 MART1−/SMA+ cells were 
considered fibroblasts; 5 MART1−/CD68+ cells were considered macrophages. 
Figure 1. Peritumoral stromal cells express the melanoma-derived oncogenic BRAFV600E protein.
(a,b) Tissue samples of a patient with BRAFV600E melanoma stained for the melanoma marker
melanoma antigen recognized by T-cells (MART1) (red), the BRAFV600E mutant protein (brown)
and hematoxylin (blue). Brown arrows indicate peritumoral MART1´/BRAFV600E+ cells displaying
fibroblast (a) or macrophage (b) morphology. Blue arrows indicate MART1´/BRAFV600E´ stromal cells
(light blue from hematoxylin). Red lines indicate MART1+ melanoma cells. Black bars indicate 50 µm.
Table 1. Peritumoral fibroblasts and macrophages in BRAFV600E melanoma carry the melanoma-derived
BRAFV600E mutation at the genetic level.
Tissue 1
Npos/Nex 2,3
Fibroblasts 4 Dissected Macrophages 5 Dissected
BRAFV600E primary melanoma 2/2 1/1
BRAFV600E melanoma metastasis 2/4 2/4
Histologically tumor-free tissue (from
patients with BRAFV600E melanoma) 0/4 1/3
BRAFWT primary melanoma 0/4 0/1
1 Tissue samples were dual-stained either with melanoma antigen recognized by T-cells (MART1) & smooth
mu cle actin (SMA) or with MART1 & CD68 and examined by a certified pathologist (IBN); 2 Npos: numb r of
patients where BRAFV600E-positive peritumoral stromal cells were found; Nex: the number of patients examined;
3 Dissected cell samples were considered positive for BRAFV600E if the prevalence of the mutant allele was
higher than 0.39% (∆Ct < 8); 4 MART1´/SMA+ cells were considered fibroblasts; 5 MART1´/CD68+ cells were
considered macrophages.
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Figure 2. Peritumoral stromal cells contain the melanoma-derived oncogenic BRAFV600E at the  
genomic level. (a) BRAFV600E melanoma tissue sample stained for MART1 (red), smooth muscle actin 
(SMA) (brown), and hematoxylin (blue) before (left panel) and after (right panel) laser-capture 
microdissection of MART1−/SMA+ fibroblasts (white line); (b,c) Tissue samples of BRAFV600E (b) 
primary melanoma and (c) melanoma metastasis stained for MART1 (red), CD68 (brown), and 
hematoxylin (blue) before (left panels) and after (right panels) laser-capture microdissection of 
MART1−/CD68+ macrophages (black line). Black bars indicate 150 µm. 
These results indicate that some peritumoral stromal cells contain a melanoma-derived 
oncogene at both the DNA and protein levels. The possible recurrent tumor-initiating potential of 
these cells is supported by our clinical observations of the local recurrence rate in our melanoma 
patients diagnosed before 1998. Patients who had primary melanoma removed completely, based on 
a clinical diagnosis of a non-melanoma skin lesion and with histologically tumor-free excision 
margins developed local recurrence significantly more often (p = 0.7 × 10−5, 12 out of 228 patients) than 
patients with melanomas excised with 5-cm margins (8 out of 935 patients), implying that recurrent-
tumor-initiating cells could indeed be present in the peritumoral stroma of malignant melanoma. 
3. Discussion 
After the complete resection of primary cutaneous melanoma, patients occasionally develop 
local recurrence, which is considered an independent prognostic factor [1]. This can be explained by 
hidden tumor-initiating cells containing tumor-derived genetic information as local minimal residual 
disease in the peritumoral area. In addition, such tumor-derived cells can also spread to distant areas 
such as lymph nodes. 
Tumor cells are commonly identified during routine histological assessments using markers that 
are often insufficiently sensitive to distinguish tumor cells from stromal cells, which is supported by 
additional genetic analyses of sentinel lymph nodes [19]. The possible role of isolated tumor cells in 
the sentinel lymph node is debated, and the predictive value of additional diagnostic approaches, 
such as melanoma-marker detection at the mRNA level, to date, is inconclusive [20]. Nevertheless, 
some studies using enhanced pathological assessments have found a link between the presence of 
single tumor cells in the sentinel lymph node and worse disease outcome compared with completely 
tumor-free sentinel lymph nodes [21–23], and other improved tumor detection methods, such as 
Figure 2. Peritumoral stromal cells contain the melanoma-derived oncogenic BRAFV600E at the genomic
level. (a) BRAFV600E melanoma tissue sample stained for MART1 (red), smooth muscle actin (SMA)
(brown), and hematoxylin (blue) before (left panel) and after (right panel) laser-capture microdissection
of MART1´/SMA+ fibroblasts (white line); (b,c) Tissue samples of BRAFV600E (b) primary melanoma
and (c) melanoma metastasis stained for MART1 (red), CD68 (brown), and hematoxylin (blue) before
(left panels) and after (right panels) laser-capture microdissection of MART1´/CD68+ macrophages
(black line). Black bars indicate 150 µm.
These results indicate that some peritumoral stromal cells contain a melanoma-derived oncogene
at both the DNA and protein levels. The possible recurrent tumor-initiating potential of these cells is
supported by our clinical observations of the local recurrence rate in our melanoma patients diagnosed
before 1998. Patients who had primary melanoma removed completely, based on a clinical diagnosis
of a non-melanoma skin lesion and with histologically tumor-free excision margins developed local
recurrence significantly more often (p = 0.7ˆ 10´5, 12 out of 228 patients) than patients with melanomas
excised with 5-cm margins (8 out of 935 patients), implying that recurrent-tumor-initiating cells could
indeed be present in the peritumoral stroma of malignant melanoma.
3. Discussion
After the complete resection of primary cutaneous melanoma, patients occasionally develop local
recurrence, which is considered an independent prognostic factor [1]. This can be explained by hidden
tumor-initiating cells containing tumor-derived genetic information as local minimal residual disease
in the peritumoral area. In addition, such tumor-derived cells can also spread to distant areas such as
lymph nodes.
Tumor cells are commonly identified during routine histological assessments using markers that
are often insufficiently sensitive to distinguish tumor cells from stromal cells, which is supported by
additional genetic analyses of sentinel lymph nodes [19]. The possible role of isolated tumor cells
in the sentinel lymph node is debated, and the predictive value of additional diagnostic approaches,
such as melanoma-marker detection at the mRNA level, to date, is inconclusive [20]. Nevertheless,
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some studies using enhanced pathological assessments have found a link between the presence of
single tumor cells in the sentinel lymph node and worse disease outcome compared with completely
tumor-free sentinel lymph nodes [21–23], and other improved tumor detection methods, such as
quantitative immunocytochemistry combined with single-cell comparative genomic hybridization,
have been found to better predict patient survival and disease outcome [24]. The incomplete removal
of tumor cells often results in a higher recurrence rate: small excision margins lead to a more frequent
tumor recurrence even if the excision margins are assessed to be tumor-free [2,25–27]. These data
imply that recurrent-tumor-initiating cells with an altered phenotype could indeed be present in the
peritumoral stroma of malignant melanoma, allowing them to remain undetected during routine
diagnostic procedures.
In this study, we examined patient-derived melanoma tissue samples and detected peritumoral
cells displaying stromal cell phenotype but carrying the oncogenic BRAFV600E mutation characteristic
of the adjacent melanoma cells. First, we detected the mutated protein with a mutation-specific
antibody. Even though nonspecific staining of the antibody in peritumoral mononuclear cells have
been reported [28,29], the fact that peritumoral fibroblasts were also positive argues for a specific
signal. Moreover, we only observed positivity in peritumoral cells adjacent to BRAFV600E melanoma.
Nevertheless, to confirm the presence of the oncogene in these cells, we also performed genomic
analyses and showed that the mutation is also present in cells with a stromal cell phenotype adjacent
to BRAFV600E melanoma cells at the genetic level. We believe the mutation originates from tumor cells,
as we did not detect the mutation in the stroma of BRAFWT melanoma samples. Possible mechanisms
for the transfer of tumor-derived information to stromal cells include tumor-stromal cell fusion,
exosomal protein transfer and the phagocytosis of tumor debris. However, subpopulations of
peritumoral stromal cells carried the BRAFV600E mutation not only at protein but also at genomic level,
suggesting cell fusion as the underlying mechanism. It is important to mention that, since melanoma
cells can lose MART1 expression, especially on the periphery of the tumor, cell morphology and the
expression patterns of CD68 or SMA were all taken into account during the process of peritumoral
cell identification.
Cell fusion studies based on in vitro observations and mouse models suggest that cell fusion can
confer an evolutionary benefit, such as increased metastatic potential [30] or drug resistance [31] to
certain tumor–stromal cell hybrid clones. However, the majority of in vitro spontaneously formed
hybrid cells undergo apoptosis [32], most likely as a result of mitotic stress. Therefore, it is possible
that tumor stromal cell fusion is rather an antitumor mechanism, eliminating most of the hybrid tumor
cells but occasionally giving rise to highly malignant tumor cell clones.
Studies in mice [33] imply that cell fusion may also take place in human tumors in vivo. However,
it is very difficult to detect tumor–stromal cell fusion on a genetic level in humans. To address this
difficulty, tumors developing in patients who have received bone marrow transplants have been
investigated: genetic material originating from the donor was detected in the patients’ tumor cells [34,35],
strongly suggesting a fusion event between recipient tumor cells and donor hemopoietic cells. However,
inflammation resulting from treatment (e.g., whole body irradiation or chemotherapeutics) preceding
bone-marrow transplantation has been reported to promote cell fusion [36–38]; therefore, further
studies investigating fusion between tumor and stromal cells are clearly required.
Nevertheless, human in vivo studies demonstrating the relevance of tumor–stromal cell fusion in
the clinical diagnosis or treatment of cancer have been lacking.
In conclusion, our results suggest that peritumoral stromal cells contain melanoma-specific
oncogenic properties such as the BRAFV600E mutation derived from the neighboring tumor cells,
potentially as a result of cell fusion. Based on the literature data, these cells, following a reversal to a
tumorous phenotype [12], can possibly contribute to tumor recurrence. These cells are phenotypically
indistinguishable from peritumoral stromal cells and are therefore not accurately detectable by
routine histological assessments. Our results highlight the importance of genetic analysis and
mutation-specific antibodies, especially in the case of histologically tumor-free tissue samples,
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for which improved methods for the detection of tumor cells have already been shown to better predict
survival and outcome. Although yet to be confirmed in clinical trials, the use of genetic analyses and
mutation-specific antibodies could have important prognostic and therapeutic consequences and could
enable the detection of recurrent-tumor-initiating cells.
4. Experimental Section
4.1. Tissue Samples and Determination of BRAF Mutational Status
Tissue samples from n = 11 patients with BRAFV600E and n = 5 patients with BRAFWT melanoma
were examined for BRAFV600E protein expression. The corresponding patient numbers for genetic
analyses were n = 11 in the case of BRAFV600E melanoma and n = 8 in the case of BRAFWT melanoma.
The BRAF mutational status of melanomas was determined with cobas® 4800 BRAFV600 Mutation
Test (Roche Molecular Diagnostics, Pleasanton, CA, USA).
4.2. Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections of patients with BRAFV600E malignant
melanoma were stained with rabbit monoclonal MART1 (clone A19-P, DB Biotech, Kosice, Slovakia),
mouse monoclonal SMA (clone 1A4, DAKO, Glostrup, Denmark), CD68 (clone PG-M1, DAKO),
and BRAFV600E (Clone VE1, Springbio, Pleasanton, CA, USA) primary antibodies. The Bond Polymer
Refine Detection Kit and the ChromoPlex 1 Dual Detection Kit (both from Leica, Wetzlar, Germany)
were used for the visualization of single and dual histochemical staining, respectively, according to
the manufacturer’s instructions. All immunohistochemical staining was scanned with a Pannoramic
MIDI Slide Scanner (3DHISTECH Ltd., Budapest, Hungary) and analyzed with Pannoramic Viewer
software (3DHISTECH Ltd.).
4.3. Laser-Capture Microdissection and Detection of the BRAFV600E Allele
30–100 cells were dissected from tissue sections stained either with MART1 and SMA or with
MART1 and CD68 using a Palm Microbeam (Carl Zeiss Microscopy, Jena, Germany). Samples were
digested with proteinase K (QIAGEN, Venlo, The Netherlands). Mutant allele (BRAF_476_mu) and
gene reference (Braf_rf) TaqMan® Mutation Detection Assays (Life Technologies, Carlsbad, CA,
USA) were used to detect the BRAFV600E mutant allele in the dissected samples. Samples with
∆Ct (Ctmut ´ Ctref) < 8 and Ctmut < 40 were considered carrying the mutant allele. MART1+
tumor cells dissected from BRAFWT and BRAFV600E melanoma were used as negative and positive
controls, respectively.
4.4. Statistical Analysis
Local recurrence rate in melanoma patients were compared with the Fisher’s exact test. The level
of significance was set to 0.05.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/
17/6/980/s1.
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